Literature DB >> 24920400

Minorities, men, and unmarried amyotrophic lateral sclerosis patients are more likely to die in an acute care facility.

Stephen A Goutman1, Dustin G Nowacek, James F Burke, Kevin A Kerber, Lesli E Skolarus, Brian C Callaghan.   

Abstract

Studies suggest that dying at home is a more favorable experience. This study investigated where amyotrophic lateral sclerosis (ALS) patients die and the patient demographics associated with dying in an acute care facility or nursing home compared to home or hospice. Centers for Disease Control and Prevention Multiple Cause Mortality Files from 2005 to 2010 were used to identify ALS patients and to classify place of death. Multinomial logistic regression was used to determine the association between patient demographics and place of death. Between 2005 and 2010, 40,911 patients died of ALS in the United States. Place of death was as follows: home or hospice facility 20,231 (50%), acute care facility (25%), and nursing home (20%). African Americans (adjusted multinomial odds ratio (aMOR) 2.56, CI 2.32-2.83), Hispanics (aMOR 1.44, CI 1.30-1.62), and Asians (aMOR 1.87, CI 1.57-2.22) were more likely to die in an acute care facility, whereas females (aMOR 0.76, CI 0.72-0.80) and married individuals were less likely. Hispanics (aMOR 0.68, CI 0.58-0.79) and married individuals were less likely to die in a nursing home. In conclusion, minorities, men, and unmarried individuals are more likely to die in an acute care facility. Further studies are needed to better understand place of death preferences.

Entities:  

Keywords:  End of life care; amyotrophic lateral sclerosis; place of death; quality of life

Mesh:

Year:  2014        PMID: 24920400      PMCID: PMC4681497          DOI: 10.3109/21678421.2014.924143

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  14 in total

Review 1.  Ethnic variation in the incidence of ALS: a systematic review.

Authors:  Simon Cronin; Orla Hardiman; Bryan J Traynor
Journal:  Neurology       Date:  2007-03-27       Impact factor: 9.910

Review 2.  Factors influencing death at home in terminally ill patients with cancer: systematic review.

Authors:  Barbara Gomes; Irene J Higginson
Journal:  BMJ       Date:  2006-02-08

Review 3.  Where people die: a multilevel approach to understanding influences on site of death in America.

Authors:  Andrea Gruneir; Vincent Mor; Sherry Weitzen; Rachael Truchil; Joan Teno; Jason Roy
Journal:  Med Care Res Rev       Date:  2007-08       Impact factor: 3.929

4.  Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health.

Authors:  Alexi A Wright; Nancy L Keating; Tracy A Balboni; Ursula A Matulonis; Susan D Block; Holly G Prigerson
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

5.  Factors considered important at the end of life by patients, family, physicians, and other care providers.

Authors:  K E Steinhauser; N A Christakis; E C Clipp; M McNeilly; L McIntyre; J A Tulsky
Journal:  JAMA       Date:  2000-11-15       Impact factor: 56.272

6.  Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study.

Authors:  T Zaldivar; J Gutierrez; G Lara; M Carbonara; G Logroscino; O Hardiman
Journal:  Neurology       Date:  2009-05-12       Impact factor: 9.910

7.  Family perspectives on end-of-life care at the last place of care.

Authors:  Joan M Teno; Brian R Clarridge; Virginia Casey; Lisa C Welch; Terrie Wetle; Renee Shield; Vincent Mor
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

8.  Amyotrophic lateral sclerosis: analysis of ALS cases in a predominantly admixed population of Ecuador.

Authors:  Miriam Bucheli; Andres Andino; Mayra Montalvo; Jose Cruz; Nazem Atassi; James Berry; Johnny Salameh
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-11-18       Impact factor: 4.092

9.  No evidence for a large difference in ALS frequency in populations of African and European origin: a population based study in inner city London.

Authors:  Ricardo Rojas-Garcia; Kirsten M Scott; Jose Carlos Roche; William Scotton; Naomi Martin; Anna Janssen; Laura H Goldstein; P Nigel Leigh; Cathy M Ellis; Christopher E Shaw; Ammar Al-Chalabi
Journal:  Amyotroph Lateral Scler       Date:  2012-01

10.  Family members' perceptions of end-of-life care across diverse locations of care.

Authors:  Romayne Gallagher; Marian Krawczyk
Journal:  BMC Palliat Care       Date:  2013-07-20       Impact factor: 3.234

View more
  5 in total

Review 1.  Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials.

Authors:  Stephen A Goutman; Masha G Savelieff; Stacey A Sakowski; Eva L Feldman
Journal:  Expert Opin Investig Drugs       Date:  2019-06-12       Impact factor: 6.206

Review 2.  Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Stephen A Goutman; Kevin S Chen; Eva L Feldman
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

3.  Rates and risks for late referral to hospice in patients with primary malignant brain tumors.

Authors:  Eli L Diamond; David Russell; Maria Kryza-Lacombe; Kathryn H Bowles; Allison J Applebaum; Jeanne Dennis; Lisa M DeAngelis; Holly G Prigerson
Journal:  Neuro Oncol       Date:  2015-08-09       Impact factor: 12.300

4.  Caregivers' View of Socio-Medical Care in the Terminal Phase of Amyotrophic Lateral Sclerosis-How Can We Improve Holistic Care in ALS?

Authors:  Katharina Linse; Elisa Aust; René Günther; Andreas Hermann
Journal:  J Clin Med       Date:  2022-01-04       Impact factor: 4.241

5.  Caregiver burden in amyotrophic lateral sclerosis: A systematic review.

Authors:  Jessica de Wit; Leonhard A Bakker; Annerieke C van Groenestijn; Leonard H van den Berg; Carin D Schröder; Johanna M A Visser-Meily; Anita Beelen
Journal:  Palliat Med       Date:  2017-07-03       Impact factor: 4.762

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.